Alfresa Holdings Corporation
Alfresa Holdings Corporation
Your view on ARHCF
Overview
What the company does, where it operates, and who runs it.
About Alfresa Holdings Corporation
- Industry
- Medical - Distribution
- Sector
- Healthcare
- CEO
- Ryuji Arakawa
- Headquarters
- 1-1-3 Otemachi, Tokyo, JP
- Industry
- Medical - Distribution
- Sector
- Healthcare
- CEO
- Ryuji Arakawa
- Headquarters
- 1-1-3 Otemachi, Tokyo, JP
Alfresa Holdings Corporation, through its subsidiaries, engages in the manufacture, wholesale, marketing, and import/export of pharmaceuticals, diagnostic reagents, and medical devices/equipment in Japan and internationally.
It is involved in the ethical pharmaceuticals wholesaling business that offers diagnostic reagents and medical devices/equipment to hospitals, clinics, and dispensing pharmacies.
The company also engages in self-medication products wholesaling business that offers over-the-counter drugs, including health foods, supplements, and other products to drug stores and pharmacies.
In addition, it manufactures and markets active pharmaceutical ingredients, pharmaceuticals, diagnostic reagents, and medical devices, as well as undertakes contract manufacturing of pharmaceuticals. Further, the company's medical-related business includes its dispensing pharmacy and other medical-related activities.
Alfresa Holdings Corporation was incorporated in 2003 and is based in Tokyo, Japan.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Alfresa Holdings Corporation, and the rating behind it. ARHCF last traded at $11.87, 10.6× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Alfresa Holdings Corporation. Starting points for Alfresa Holdings Corporation: P/E 10.6, EPS $219.33, beta -0.12 — an Medical - Distribution name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Alfresa Holdings Corporation. Alfresa Holdings Corporation does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Alfresa Holdings Corporation. Trailing twelve-month EPS for Alfresa Holdings Corporation stands at $219.33. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Alfresa Holdings Corporation. Alfresa Holdings Corporation has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Alfresa Holdings Corporation valued side by side against its closest peers. Alfresa Holdings Corporation is measured against Medical - Distribution peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Alfresa Holdings Corporation, and how their positions are changing. At a $2.16B market value, institutional positions materially move Alfresa Holdings Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Alfresa Holdings Corporation executives and directors. Shares of Alfresa Holdings Corporation have traded between $11.87 and $11.87 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Alfresa Holdings Corporation. Alfresa Holdings Corporation is a $2.16B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Alfresa Holdings Corporation. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Alfresa Holdings Corporation. Coverage tracks Alfresa Holdings Corporation within Medical - Distribution (Healthcare). Press releases and market coverage, newest first.